- Report
- April 2024
- 255 Pages
Global
From €4787EUR$4,950USD£4,054GBP
- Report
- March 2024
- 198 Pages
Global
From €3263EUR$3,374USD£2,763GBP
€3625EUR$3,749USD£3,070GBP
- Report
- March 2024
- 125 Pages
Global
From €5754EUR$5,950USD£4,873GBP
- Report
- October 2023
- 189 Pages
Global
From €4739EUR$4,900USD£4,013GBP
- Report
- February 2024
- 115 Pages
Global
From €4594EUR$4,750USD£3,890GBP
- Report
- January 2024
- 145 Pages
Global
From €4110EUR$4,250USD£3,481GBP
- Report
- January 2022
- 200 Pages
Global
From €7253EUR$7,500USD£6,142GBP
- Report
- January 2022
- 60 Pages
Global
From €3820EUR$3,950USD£3,235GBP
- Report
- October 2023
- 89 Pages
Global
From €3500EUR$3,877USD£3,068GBP
- Report
- April 2023
- 147 Pages
Global
From €5801EUR$5,999USD£4,913GBP
- Book
- January 2016
- 160 Pages
- Book
- July 2012
- 448 Pages
- Book
- October 2022
North America
Cachexia is a condition that affects many patients receiving palliative care. It is characterized by a combination of muscle wasting, fatigue, and anorexia. It is often associated with a variety of chronic illnesses, including cancer, HIV/AIDS, and chronic obstructive pulmonary disease. Cachexia can lead to a decrease in quality of life and an increase in mortality.
The cachexia market within the context of palliative care is focused on providing treatments and therapies to improve the quality of life of patients suffering from cachexia. These treatments may include nutritional support, physical activity, and medications. Additionally, there are a variety of supportive services available to help patients manage their symptoms and improve their overall wellbeing.
Companies in the cachexia market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more
